Register for patients with severe asthma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to establish a clinical register for patients suffering from severe asthma across multiple centers in Switzerland. By collecting comprehensive data on the frequency, phenotype, and treatment of severe asthma, the study seeks to optimize diagnostic evaluations and therapeutic approaches. Patients will be followed for up to 15 years, with regular assessments of their asthma control using the Asthma Control Test (ACT) and other relevant parameters. The study addresses the significant gap in reliable information regarding severe asthma management.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* In- and outpatients
* Age ≥ 0 year
* Informed consent as documented by signature

Adults:

"Asthma which requires treatment with guidelines suggested medications for GINA steps 4-5 asthma:

* High level therapy:

  1. high dose ICS with ≥ 1000 μg beclomethasone (powder) or equivalent in combination with LABA or leukotriene modifier/theophylline) for the previous year or
  2. Daily long-term therapy with systemic corticosteroids (CS) for ≥50% of the previous year to prevent it from becoming "uncontrolled" or which remains "uncontrolled" despite this therapy or
  3. Therapy with monoclonal antibodies independent from the co-therapy
* Middle level therapy:

Protokollsynopsis SAR Version 01 16.01.2019 Seite 4/10 a) Daily long-term therapy with medium-to high-dose ICS (≥500 μg Beclomethason (powder) or equivalent in combination with LABA or leukotriene modifier/theophylline) for the previous year and uncontrolled asthma defined as at least one of the following:

* Poor symptom control: ACQ consistently \>1.5, ACT \<20 (or "not well controlled" by NAEPP/GINA guidelines).
* Frequent severe exacerbations: two or more bursts of systemic CS (\>3 days each) in the previous year.
* Serious exacerbations: at least one hospitalization, ICU stay or mechanical ventilation in the previous year.
* Airflow limitation: after appropriate bronchodilator withhold FEV1 \<80% predicted (in the face of reduced FEV1/FVC defined as less than the lower limit of normal).
* Controlled asthma that worsens on tapering of these high doses of ICS or systemic CS (or additional biologics). The presence of any one of the following exclusion criteria will lead to exclusion of the patients:
* Life-expectancy \<6 months
* Insufficient knowledge of project language

Children:

The criteria for severe or difficult asthma in children and adolescents are considered fulfilled in the case of insufficient symptom control in the last year despite medium/high antiinflammatory long-term therapy:

* age 0-18 years, at time of inclusion
* diagnosis of bronchial asthma made by a physician
* differential diagnoses excluded
* good compliance and trained inhalation technique
* treatment with biological approved for the treatment of severe asthma (currently only omalizumab) or

Proof of:

a) Positive Bronchodilation-test (≥12% increase in FEV1 after SABA) or b) Significant bronchial hyperresponsiveness after nonspecific provocation (e.g., with Methacholine or treadmill) according to ATS criteria (AJRCCM 2000)

* High level of therapy:

  1. Prolonged therapy with high dose inhaled steroid (ICS) (\> 400 μg Budesonide equivalent /\> 200 μg fluticasone alone); or
  2. Daily long-term therapy with medium- to high-dose ICS (≥ 400 μg Budesonide equivalent / ≥200 μg fluticasone) in combination with long-acting betaagonists and / or leukotriene receptor antagonist and / or theophylline; or
  3. Therapy with oral steroids fixed ≥3 last months.
* Insufficient asthma control

  a) Inadequate symptom control after NVL in the last 4 weeks: Protokollsynopsis SAR Version 01 16.01.2019 Seite 5/10
  * ≥3 x weekly asthma symptoms or use of ondemand medication; Or:
  * limited activity due to asthma; Or:
  * any symptoms at night; or b. Exacerbation(s) ≥1 last year that required treatment with systemic steroids and / or inpatient treatment c. limited lung function:
  * pathological Tiffeneau quotient or FEV1 at inclusion.
* Submission of a written consent (parent/ legal guardian).

Exclusion Criteria:

* Life-expectancy \<6 months · Insufficient knowledge of project language

Where it's running

• Cantonal Hospital Baselland Liestal
  Liestal, Basel-Landschaft, Switzerland Recruiting
• Universitätsklinik für Pneumologie, Inselspital
  Bern, Switzerland Recruiting
• Pneumologie, Kantonsspital Graubünden
  Chur, Switzerland Recruiting
• Klinik für Pneumologie, Hochgebirgsklinik Davos
  Davos, Switzerland Recruiting
• Hôpitaux Universitaires Genève
  Geneva, Switzerland Recruiting
• Centre hospitalier universitaire vaudoise
  Lausanne, Switzerland Recruiting

Study contacts

• Principal investigator: Jörg Leuppi — Kantonsspital Baselland Liestal
• Study coordinator: Jörg Leuppi
• Email: Joerg.leuppi@ksbl.ch
• Phone: +41619252181

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Structured physical activity program added to tezepelumab for adults with severe asthma

  A 12-week program to help adults with severe asthma who start tezepelumab see if adding guided physical activity improves activity levels and chances of remission.

  Recruiting University of Leeds · Leeds · NCT07735494

• Exercise program for adults with severe asthma starting biologics

  A tailored exercise program is being tested to see if it helps adults with severe asthma who are starting biologic therapy feel better and breathe better.

  Recruiting Helsinki University Central Hospital · Helsinki · NCT07655037

• Frevecitinib (KN-002) for severe asthma: a 12-week dose-ranging study

  This study tests three doses of frevecitinib vs placebo to see if it helps people with severe asthma not controlled by standard inhaled steroids and LABA therapy.

  Recruiting at 9 sites Phase 2 Kinaset Therapeutics Inc · Lancaster, California and 13 other locations · NCT07532265

• Benralizumab treatment for adults with ABPA and severe asthma

  This will test whether benralizumab helps adults (18–75) who have severe asthma with allergic bronchopulmonary aspergillosis (ABPA).

  Recruiting at 2 sites Qianfoshan Hospital · Jinan, Shandong and 1 other locations · NCT07530770

• Tezepelumab to reduce maintenance medication in people with severe asthma

  This will test whether people aged 12–80 with severe asthma in China who start tezepelumab can safely reduce their regular maintenance medicines while keeping asthma controlled.

  Recruiting at 59 sites Phase 3 AstraZeneca · Beijing and 74 other locations · NCT07363642

• GB-0895 as an add-on treatment for severe uncontrolled asthma in adolescents and adults

  This test tries to see if adding GB-0895 every six months helps adolescents and adults whose severe asthma isn't controlled by inhaled steroids and other controllers.

  Recruiting at 158 sites Phase 3 Generate Biomedicines · Bakersfield, California and 157 other locations · NCT07359846

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.